 Market.webp)
Oculopharyngeal Muscular Dystrophy Market size is poised to surpass USD 10 Billion by the end of 2036, growing at a CAGR of 14% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the oculopharyngeal muscular dystrophy was USD 4 Billion. The market growth is on account of the rising prevalence of OPMD among the growing middle-aged population. According to MedlinePlus, muscular disease affects 1-100,000 people, especially occurring in the middle-aged population mostly after the age of 45. Affected patients can usually first experience weakness of the muscles in both eyelids that causes droopy eyelids and develop weakness in throat muscles making it hard for the patient to see or swallow.
Furthermore, other factors that are believed to fuel the growth of the market are advancements in symptomatic treatments like CP myotomy, and gastrostomy feeding tube insertion which are mostly aimed at reducing the symptoms and gaining signs for the comfort and well-being of the patients. This factor provides an additional opportunity for key players present in the market to expand their research and development activities.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~14% |
|
Base Year Market Size (2023) |
~ USD 4 Billion |
|
Forecast Year Market Size (2036) |
~ USD 10 Billion |
|
Regional Scope |
|
Treatment (Symptomatic & Disease-Modifying)
The symptomatic segment in the oculopharyngeal muscular dystrophy market is estimated to gain the largest revenue share of about 59% in the year 2036. The segment growth can be attributed to the burgeoning geriatric population which makes the populace more susceptible to oculopharyngeal muscular dystrophy.According to surveys by various firms and organizations this disorder has been reported approximately in 29 countries. Additionally, the high cost and risk of side effects of surgery and disease-modifying treatments has led to the rise of the segment as symptomatic treatment which mostly consists of therapies like the wide range of motion stretching exercises, braces which add mobility and function by providing support for weakened muscles, sleep apnea device that helps improve oxygen delivery during the night.
End-User (Hospitals, Diagnostic Centers, Clinics)
The hospital segment in the oculopharyngeal muscular dystrophy market is estimated to gain the largest revenue share of about 42% in the year 2036. The availability of hospitals in every region of the world alongside the presence of advanced therapeutic medicinal products for the treatment of oculopharyngeal muscular dystrophy is expected to drive the segment growth. To make reference, as of 2021, there are reportedly around 167,000 hospitals in the world. Asia has over 100,000 hospitals alone. Additionally, the rising inclination towards hospitals for receiving treatment by the population owning to the easy accessibility of trained medical staff and professionals among other factors attributed to the segment’s market growth.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Distribution Channels |
|
|
End-Users |
|
North American Market Forecast
The North America oculopharyngeal muscular dystrophy market estimated to hold the largest revenue share about 36% during the forecast period. The growth of the market can be attributed to the growing frequency of Oculopharyngeal muscular dystrophy disorder in the region. For instance, the highest prevalence rate of Oculopharyngeal muscular dystrophy 1/1000 people can be found in French Canadian population of Quebec Canada. In USA around 1/100,000 people are diagnosed with Oculopharyngeal muscular dystrophy. Furthermore, high health awareness among the population along with easy access to quality healthcare in developed region is attributed to rapid market expansion in the region during the forecast period. In addition to that, the region’s rising technological healthcare industry and expanding expenditure are also anticipated to boost the market growth in the upcoming years.
APAC Market Forecast
The Asia Pacific oculopharyngeal muscular dystrophy market is estimated to the second largest, revenue share of about 29% by the end of 2036. The market’s expansion can be attributed majorly to the soaring prevalence of different chronic diseases and prolonged pain, ache and infection among the people living in the region. According to studies across Asia, the prevalence of chronic pain in adults has been reported to vary greatly, ranging from 7% in Malaysia to 60% in Cambodia and Northern Iraq. Older adults are more likely to experience chronic pain, with prevalence rates as high as 40% to 90%. Additionally, the rising focus on health and fitness coupled with government initiatives which promote a healthy lifestyle is anticipated to increase the adoption rate of Oculopharyngeal muscular dystrophy. These factors are estimated to expand the market size in the forecast period.
 Market Size.webp)
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?